Holen Sie sich die Stockscreener-App
0.1319
7.11%
-0.0101
Schlusskurs vom Vortag:
$0.142
Offen:
$0.1355
24-Stunden-Volumen:
13.55M
Relative Volume:
0.36
Marktkapitalisierung:
$18.26M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-27.39M
KGV:
-0.0785
EPS:
-1.6803
Netto-Cashflow:
$-2.09M
1W Leistung:
+35.98%
1M Leistung:
+24.79%
6M Leistung:
-50.97%
1J Leistung:
+0.00%
1-Tages-Spanne:
$0.1191
$0.1365
1-Wochen-Bereich:
$0.0961
$0.1425
52-Wochen-Spanne:
$0.0709
$2.10
Aspire Biopharma Holdings Inc Stock (ASBP) Company Profile
Firmenname
Aspire Biopharma Holdings Inc
Sektor
Branche
Telefon
561-704-8527
Adresse
23150 FASHION DRIVE, SUITE 232, ESTERO
Vergleichen Sie ASBP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ASBP
Aspire Biopharma Holdings Inc
|
0.1319 | 19.66M | 0 | -27.39M | -2.09M | -1.6803 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.36 | 115.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.87 | 81.34B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.65 | 52.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
840.95 | 51.59B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.04 | 37.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Aspire Biopharma Holdings Inc Aktie (ASBP) Neueste Nachrichten
Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements - South Bend Tribune
Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack) - Livingston Daily
Aspire Biopharma Provides Q3 2025 Business Update - Montgomery Advertiser
Aspire Biopharma Holdings, Inc. Announces CEO Transition - aberdeennews.com
Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member - Petoskey News-Review
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation - Pensacola News Journal
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Aspire Biopharma Holdings, Inc. Warrant 2025-18.02.30 on Aspire Bio Hldgs Revenue Breakdown – NASDAQ:ASBPW - TradingView — Track All Markets
Aspire Biopharma Holdings, Inc. Warrant 2025-18.02.30 on Aspire Bio Hldgs - TradingView — Track All Markets
Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin - Bluffton Today
Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine - The Florida Times-Union
ASBPAI Stock Analysis - Meyka
Aspire Biopharma welcomes Ashley Paulson as Brand Ambassador - Comunicaffe International
Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Gl - The National Law Review
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Aspire Biopharma names Ashley Paulson BUZZ BOMB global brand ambassador - TipRanks
Aspire Biopharma Holdings (ASBP) Stock on Dec. 15, 2025: Nasdaq Extension, FDA Pre‑IND Momentum, and Dilution Risks Investors Are Watching - ts2.tech
Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance With Continued Listing Requirements - 富途牛牛
Aspire Biopharma Hldgs (ASBP) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Aspire Biopharma gets Nasdaq extension to meet listing requirements By Investing.com - Investing.com Nigeria
Aspire Biopharma gets Nasdaq extension to meet listing requirements - Investing.com
Finanzdaten der Aspire Biopharma Holdings Inc-Aktie (ASBP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):